Literature DB >> 3081086

Diarrhoea due to Clostridium difficile associated with antibiotic treatment in patients receiving dialysis: the role of cross infection.

A D Cumming, B J Thomson, J Sharp, I R Poxton, A Fraser.   

Abstract

Entities:  

Mesh：

Year:  1986        PMID： 3081086      PMCID： PMC1339209          DOI： 10.1136/bmj.292.6515.238

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  4 in total

1.  Clostridium difficile-associated colitis: cross infection in predisposed patients with renal failure.

Authors:  D Bruce; C Ritchie; L C Jennings; K L Lynn; R R Bailey; H B Cook
Journal:  N Z Med J       Date:  1982-04-28

2.  Peritonitis in continuous ambulatory peritoneal dialysis. Laboratory and clinical studies.

Authors:  R Gokal; J M Ramos; D M Francis; R E Ferner; T H Goodship; G Proud; A J Bint; M K Ward; D N Kerr
Journal:  Lancet       Date:  1982-12-18       Impact factor: 79.321

3.  Immunochemical fingerprinting of Clostridium difficile strains isolated from an outbreak of antibiotic-associated colitis and diarrhoea.

Authors:  I R Poxton; B Aronsson; R Möllby; C E Nord; J G Collee
Journal:  J Med Microbiol       Date:  1984-06       Impact factor: 2.472

4.  Clostridium difficile and the aetiology of pseudomembranous colitis.

Authors:  H E Larson; A B Price; P Honour; S P Borriello
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321
  4 in total
  10 in total

1.  Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital.

Authors:  Tara N Palmore; SeJean Sohn; Sharp F Malak; Janet Eagan; Kent A Sepkowitz
Journal:  Infect Control Hosp Epidemiol       Date:  2005-08       Impact factor: 3.254

2.  Clostridium difficile plasmid isolation as an epidemiologic tool.

Authors:  C Clabots; S Lee; D Gerding; M Mulligan; R Kwok; D Schaberg; R Fekety; L Peterson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

3.  Typing of Clostridium difficile causing diarrhoea in an orthopaedic ward.

Authors:  I McKay; J E Coia; I R Poxton
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

4.  Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery.

Authors:  G Privitera; P Scarpellini; G Ortisi; G Nicastro; R Nicolin; F de Lalla
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

5.  Development and application of a multiple typing system for Clostridium difficile.

Authors:  D E Mahony; J Clow; L Atkinson; N Vakharia; W F Schlech
Journal:  Appl Environ Microbiol       Date:  1991-07       Impact factor: 4.792

6.  Survey of incidence of Clostridium difficile infection in Canadian hospitals and diagnostic approaches.

Authors:  M J Alfa; T Du; G Beda
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

7.  Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea.

Authors:  F de Lalla; R Nicolin; E Rinaldi; P Scarpellini; R Rigoli; V Manfrin; A Tramarin
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

8.  Treatment of Clostridium difficile-associated disease with teicoplanin.

Authors:  F de Lalla; G Privitera; E Rinaldi; G Ortisi; D Santoro; G Rizzardini
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

9.  Estimating the financial cost of chronic kidney disease to the NHS in England.

Authors:  Marion Kerr; Benjamin Bray; James Medcalf; Donal J O'Donoghue; Beverley Matthews
Journal:  Nephrol Dial Transplant       Date:  2012-08-05       Impact factor: 5.992

10.  How do hospital professionals involved in a randomised controlled trial perceive the value of genotyping vs. PCR-ribotyping for control of hospital acquired C. difficile infections?

Authors:  Ala Szczepura; Susan Manzoor; Katherine Hardy; Nigel Stallard; Helen Parsons; Savita Gossain; Peter M Hawkey
Journal:  BMC Infect Dis       Date:  2014-03-21       Impact factor: 3.090
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.